Rockefeller Capital Management
ALLO icon

Rockefeller Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Rockefeller Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.8K Buy
13,868
+5,972
+76% +$12K ﹤0.01% 3466
2025
Q4 		$10.8K Buy
7,896
+646
+9% +$852 ﹤0.01% 3778
2025
Q3 		$8.99K Buy
+7,250
New +$8.64K ﹤0.01% 3686
2023
Q2 		– Sell
-14,702
Closed -$72K – 1814
2023
Q1 		$72K Buy
14,702
+77
+0.5% +$494 ﹤0.01% 1909
2022
Q4 		$91K Buy
14,625
+542
+4% +$5.02K ﹤0.01% 2077
2022
Q3 		$151K Buy
14,083
+1,248
+10% +$17K ﹤0.01% 1779
2022
Q2 		$146K Sell
12,835
-27,754
-68% -$246K ﹤0.01% 1752
2022
Q1 		$369K Buy
40,589
+7,943
+24% +$82.7K ﹤0.01% 1440
2021
Q4 		$486K Buy
32,646
+22,646
+226% +$400K ﹤0.01% 1331
2021
Q3 		$257K Buy
+10,000
New +$237K ﹤0.01% 1502
2021
Q1 		– Sell
-3,054
Closed -$77K – 3236
2020
Q4 		$77K Buy
+3,054
New +$99.5K ﹤0.01% 1541

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's ALLO Position: Q1 2026 in Review

Rockefeller Capital Management increased its Allogene Therapeutics (ALLO) stake by 76% in Q1 2026, buying an estimated $12K and bringing the position to 13,868 shares worth $33.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3466.

Rockefeller Capital Management first reported a position in ALLO in Q4 2020 and has held it in 11 quarters since. The position peaked at $486K in Q4 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Rockefeller Capital Management held 13,868 shares of Allogene Therapeutics worth $33.8K as of Q1 2026.
  • Rockefeller Capital Management bought 5,972 Allogene Therapeutics shares in Q1 2026, an estimated $12K.
  • Allogene Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3466 holding.
  • Rockefeller Capital Management first reported a position in Allogene Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • Rockefeller Capital Management's Allogene Therapeutics position peaked at $486K in Q4 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.